Lexicon Pharmaceuticals develops drug candidates and sells INPEFA, a heart failure treatment, from The Woodlands, Texas. LXRX reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 28 | Cantor Fitzgerald | Initiated | Buy | |
| Sep 25 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How LXRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in LXRX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LXRX is in one of them and how their past LXRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LXRX in an article yet. Here's the latest on the wider market.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. It markets INPEFA, a tablet taken once a day that is approved in the United States to lower the risk of cardiovascular death and heart failure hospitalization in adults with heart failure or related risk factors. Its drug candidates target hypertrophic cardiomyopathy, type 1 diabetes, and neuropathic pain, and it has licensed an obesity candidate to Novo Nordisk. INPEFA reaches patients through wholesalers, retail pharmacies, hospitals, and a mail order pharmacy, serving prescribers and patients.
- Headquarters
- The Woodlands, TX
- Founded
- 1995
- Website
- lexpharma.com ↗